Trius Therapeutics (TSRX) Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy
6/12/2013 8:33:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, June 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infections, today announced the publication of the results of multiple clinical and animal studies showing the company's experimental antibiotic, tedizolid phosphate (TR-701), does not interact with monamine oxidase (MAO). MAO is an enzyme involved in the regulation of neurotransmitters such as serotonin, norepinephrine and dopamine, and its inhibition can lead to serious drug-drug interactions. These results were published in the July 2013 (Volume 57 Number 7) print issue of Antimicrobial Agents and Chemotherapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by